A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

Drugs made to treat diabetes and weight loss could stop or even reverse a severe liver disease, according to a new study. The ...

Once-weekly semaglutide 2.4 mg significantly reduced steatohepatitis and liver fibrosis symptoms among adults with metabolic ...

Since its historic FDA approval in March 2024 as the first medication for the treatment of the prevalent liver disease ...

The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to a new ...

Semaglutide, a drug commonly taken for weight loss, showed marked benefits for most patients in a trial for metabolic ...

Semaglutide is the key component of weight loss and diabetes drugs like Ozempic and Wegovy, and an international team of ...

A global trial finds Wegovy and Ozempic significantly improve liver health in patients and treats those with advanced fatty ...

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.

Health Canada begins a priority review of semaglutide 2.4 mg, a weekly treatment by Novo Nordisk for MASH, a liver disease ...